| 1 |
Varatanovic S, Maier T, Al-Gboore S, Stoiber S, Kandathil SA, Quint C, Brennus C, Heiduschka G, Kadletz-Wanke L, Brkic FF. In vitro effects of gamma-secretase inhibition in HPV-positive and HPV-negative head and neck squamous cell carcinoma. Invest New Drugs 2023. [PMID: 36809443 DOI: 10.1007/s10637-023-01334-x] [Reference Citation Analysis]
|
| 2 |
Wu J, Li Y, He Q, Yang X. Exploration of the Use of Natural Compounds in Combination with Chemotherapy Drugs for Tumor Treatment. Molecules 2023;28. [PMID: 36770689 DOI: 10.3390/molecules28031022] [Reference Citation Analysis]
|
| 3 |
Koistinen H, Kovanen RM, Hollenberg MD, Dufour A, Radisky ES, Stenman UH, Batra J, Clements J, Hooper JD, Diamandis E, Schilling O, Rannikko A, Mirtti T. The roles of proteases in prostate cancer. IUBMB Life 2023. [PMID: 36598826 DOI: 10.1002/iub.2700] [Reference Citation Analysis]
|
| 4 |
Du Z, Chen X, Zhu P, Sun W, Lv Q, Cheng S, Yang X, Yu X, Want M. SOX8 Knockdown Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting the Notch Signaling Pathway. BioMed Research International 2022;2022:1-15. [DOI: 10.1155/2022/9235837] [Reference Citation Analysis]
|
| 5 |
Li WJ, Liu X, Dougherty EM, Tang DG. MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development. Cancers (Basel) 2022;14:4538. [PMID: 36139695 DOI: 10.3390/cancers14184538] [Reference Citation Analysis]
|
| 6 |
Mourkioti I, Angelopoulou A, Belogiannis K, Lagopati N, Potamianos S, Kyrodimos E, Gorgoulis V, Papaspyropoulos A. Interplay of Developmental Hippo-Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer. Cells 2022;11:2449. [PMID: 35954292 DOI: 10.3390/cells11152449] [Reference Citation Analysis]
|
| 7 |
Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res 2022;41:214. [PMID: 35773731 DOI: 10.1186/s13046-022-02406-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 8 |
Mao F, Kong Y, Liu J, Rao X, Li C, Donahue K, Zhang Y, Jones K, Zhang Q, Xu W, Liu X. Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer. Prostate 2022;82:917-32. [PMID: 35322879 DOI: 10.1002/pros.24336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Yang C, Mai Z, Liu C, Yin S, Cai Y, Xia C. Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways. Molecules 2022;27:3513. [PMID: 35684449 DOI: 10.3390/molecules27113513] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 10 |
Cai C, Zhang M, Liu L, Zhang H, Guo Y, Lan T, Xu Y, Ma P, Li S. ADAM10-cleaved ephrin-A5 contributes to prostate cancer metastasis. Cell Death Dis 2022;13:453. [PMID: 35551177 DOI: 10.1038/s41419-022-04893-8] [Reference Citation Analysis]
|
| 11 |
Pinto F, Dibitetto F, Ragonese M, Bassi P. Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives. Medical Sciences 2022;10:25. [DOI: 10.3390/medsci10020025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 12 |
Zhou MY, Bui NQ, Charville GW, Ghanouni P, Ganjoo KN. Current management and recent progress in desmoid tumors. Cancer Treatment and Research Communications 2022. [DOI: 10.1016/j.ctarc.2022.100562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Wang YX, Wu H, Ren Y, Lv S, Ji C, Xiang D, Zhang M, Lu H, Fu W, Liu Q, Yan Z, Ma Q, Miao J, Cai R, Lan X, Wu B, Wang W, Liu Y, Wang DZ, Cao M, He Z, Shi Y, Ping Y, Yao X, Zhang X, Zhang P, Wang JM, Wang Y, Cui Y, Bian XW. Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas. Signal Transduct Target Ther 2022;7:72. [PMID: 35273141 DOI: 10.1038/s41392-022-00890-7] [Reference Citation Analysis]
|
| 14 |
Zhao J, Gao S, Chen C, Li H, Wang S, Yu Y, Ming L. Screening and identification of differentially expressed long non-coding RNAs in multidrug-resistant tuberculosis. PeerJ 2022;10:e12776. [PMID: 35111403 DOI: 10.7717/peerj.12776] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 15 |
Schnepp PM, Ahmed A, Escara-Wilke J, Dai J, Shelley G, Keller J, Mizokami A, Keller ET. Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer. BMC Cancer 2021;21:1316. [PMID: 34879849 DOI: 10.1186/s12885-021-09048-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Roles of renin-angiotensin system in the regulation of prostate cancer bone metastasis: a critical review. ann urol oncol 2021. [DOI: 10.32948/auo.2021.10.20] [Reference Citation Analysis]
|
| 17 |
Wei J, Liu Z, He J, Liu Q, Lu Y, He S, Yuan B, Zhang J, Ding Y. Traditional Chinese medicine reverses cancer multidrug resistance and its mechanism. Clin Transl Oncol 2021. [PMID: 34643878 DOI: 10.1007/s12094-021-02716-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Elmarakeby HA, Hwang J, Arafeh R, Crowdis J, Gang S, Liu D, AlDubayan SH, Salari K, Kregel S, Richter C, Arnoff TE, Park J, Hahn WC, Van Allen EM. Biologically informed deep neural network for prostate cancer discovery. Nature 2021;598:348-52. [PMID: 34552244 DOI: 10.1038/s41586-021-03922-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 36] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 19 |
Lei H, Wang Z, Jiang D, Liu F, Liu M, Lei X, Yang Y, He B, Yan M, Huang H, Liu Q, Pang J. CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer. Cell Death Dis 2021;12:740. [PMID: 34315855 DOI: 10.1038/s41419-021-04027-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 20 |
Lassche G, Tada Y, van Herpen CML, Jonker MA, Nagao T, Saotome T, Hirai H, Saigusa N, Takahashi H, Ojiri H, van Engen-Van Grunsven ACH, Schalken JA, Fushimi C, Verhaegh GW. Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade. Cancers (Basel) 2021;13:3527. [PMID: 34298742 DOI: 10.3390/cancers13143527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 21 |
Lim Y, Arora S, Schuster SL, Corey L, Fitzgibbon M, Wladyka CL, Wu X, Coleman IM, Delrow JJ, Corey E, True LD, Nelson PS, Ha G, Hsieh AC. Multiplexed functional genomic analysis of 5' untranslated region mutations across the spectrum of prostate cancer. Nat Commun 2021;12:4217. [PMID: 34244513 DOI: 10.1038/s41467-021-24445-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 22 |
Du Z, Li L, Sun W, Zhu P, Cheng S, Yang X, Luo C, Yu X, Wu X. Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells. Front Oncol 2021;11:607291. [PMID: 33791203 DOI: 10.3389/fonc.2021.607291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 23 |
Bauer S, Ratz L, Heckmann-Nötzel D, Kaczorowski A, Hohenfellner M, Kristiansen G, Duensing S, Altevogt P, Klauck SM, Sültmann H. miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells. Cancers (Basel) 2021;13:964. [PMID: 33669024 DOI: 10.3390/cancers13050964] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 24 |
Maitland NJ. Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced? Cancers (Basel) 2021;13:327. [PMID: 33477370 DOI: 10.3390/cancers13020327] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 25 |
Jones K, Zhang Y, Kong Y, Farah E, Wang R, Li C, Wang X, Zhang Z, Wang J, Mao F, Liu X, Liu J. Epigenetics in prostate cancer treatment. J Transl Genet Genom 2021;5:341-56. [PMID: 35372800 DOI: 10.20517/jtgg.2021.19] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 26 |
Chen X, Yin L, Qiao G, Li Y, Li B, Bai Y, Feng F. Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer. Oncol Lett 2020;20:2997-3005. [PMID: 32782617 DOI: 10.3892/ol.2020.11823] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 27 |
Moore G, Annett S, McClements L, Robson T. Top Notch Targeting Strategies in Cancer: A Detailed Overview of Recent Insights and Current Perspectives. Cells 2020;9:E1503. [PMID: 32575680 DOI: 10.3390/cells9061503] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 20.3] [Reference Citation Analysis]
|
| 28 |
Inder S, Bates M, Ni Labhrai N, McDermott N, Schneider J, Erdmann G, Jamerson T, Flores AN, Prina-Mello A, Thirion P, Manecksha PR, Cormican D, Finn S, Lynch T, Marignol L. Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance. Sci Rep 2019;9:17325. [PMID: 31758038 DOI: 10.1038/s41598-019-53799-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 29 |
Packer JR, Hirst AM, Droop AP, Adamson R, Simms MS, Mann VM, Frame FM, O'Connell D, Maitland NJ. Notch signalling is a potential resistance mechanism of progenitor cells within patient-derived prostate cultures following ROS-inducing treatments. FEBS Lett 2020;594:209-26. [PMID: 31468514 DOI: 10.1002/1873-3468.13589] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 30 |
Rice MA, Malhotra SV, Stoyanova T. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Front Oncol. 2019;9:801. [PMID: 31555580 DOI: 10.3389/fonc.2019.00801] [Cited by in Crossref: 115] [Cited by in F6Publishing: 123] [Article Influence: 28.8] [Reference Citation Analysis]
|
| 31 |
Zhang LH, Li LH, Zhang PF, Cai YF, Hua D. LINC00957 Acted as Prognostic Marker Was Associated With Fluorouracil Resistance in Human Colorectal Cancer. Front Oncol 2019;9:776. [PMID: 31497531 DOI: 10.3389/fonc.2019.00776] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
